TNFRSF10B and neoplasm: Recently, we have generated the DR5 receptor-selective TRAIL variant DR5-B, which can bind only to the DR5 death receptor, and, as a result, it can overcome a receptor-dependent resistance of tumor cells to TRAIL [22].